Abstract PURPOSE: The incidence of anaplastic lymphoma kinase (ALK) rearrangement in pulmonary sarcomatoid carcinoma (PSC) is controversial. In this study, we aimed to reveal the reliable frequency and the clinical-pathologic characteristics of pulmonary sarcomatoid carcinoma (PSC) with ALK rearrangement in Chinese population, and to provide insight into the translatability of anti-ALK treatment in this treatment-refractory disease. METHODS: Immunohistochemistry (IHC) using a Ventana anti-ALK (D5F3) rabbit monoclonal antibody was performed in 141 PSC specimens collected from multiple medical centers. IHC-positive cases were then confirmed using ALK fluorescent in situ hybridization (FISH). The incidence rates and clinical-pathologic characteristics of ALKrearranged PSC were then analyzed. Response to ALK inhibitor crizotinib in a patient with ALK-rearranged PSC was evaluated according to the response evaluation criteria for solid tumors (RECIST) version 1.1. RESULTS: Five of 141 (3.5%) of PSCs showed ALK rearrangement-positive by IHC and then were confirmed by FISH. Two were carcinosarcomas and the other three were pulmonary pleomorphic carcinoma (PPC). Strong positive ALK rearrangement was observed in both the epithelioid and sarcomatoid components. The median age of ALKpositive patients was younger than that of ALK-negative patients. PSCs in never-smokers were more likely to harbor ALK rearrangement than those in former or current smokers (P b .05). A 40-year-old woman diagnosed with www.transonc.com 
Introduction
Pulmonary sarcomatoid carcinoma (PSC) is a rare and highly aggressive group of poorly differentiated non-small cell lung cancer (NSCLC) [1, 2] . It approximately accounts for 0.1-0.4% of all lung cancer, and encompasses five different histological subtypes: pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, carcinosarcoma, and pulmonary blastoma [3] [4] [5] . PSC usually has a higher rate of recurrence and a poorer response to conventional chemotherapy than other NSCLCs [6, 7] .
Recent comprehensive genetic studies and clinical observations are starting to uncover the oncogenic underpinnings and potential molecular targets of PSC [8] [9] [10] [11] . Previously, several small sample size studies have reported no anaplastic lymphoma kinase (ALK) rearrangement in PSC, yet recently, some isolated case reports have shown patients of PSC harboring ALK rearrangement [12] [13] [14] . Because the frequency is controversial, the value of routine detection of ALK rearrangement and the clinical benefit from anti-ALK treatment in PSC remain unknown. Larger sample size studies to uncover the accurate incidence rates of ALK rearrangement in PSC are urgent. Therefore, we performed a cohort study in a large series of PSC from multiple centers in China to reveal the frequency and the clinical-pathologic characteristics of PSC with ALK rearrangement.
Materials and Methods

Patients and Specimens
This study was approved by the institutional review board of every participating institution. We collected 167 PSCs from six medical centers in many different areas, including the southern, northern, eastern, and western parts of China, from November 1999 to October 2015. A total of 26 cases were excluded because of lacking enough tumor tissues. Eventually, 141 PSCs were enrolled for ALK rearrangement detection and further analysis. All patients were confirmed through a PSC diagnosis by an experienced pathologist (Y.Z.) according to the 2015 WHO criteria of lung cancer [5] . Clinical parameters and tumor features were tabulated from the medical records of the patients, including EGFR and KRAS mutational status where available. Clinical staging was performed according to the American Joint Committee on Cancer (AJCC, 7th edition).
Immunochemistry staining of ALK rearrangement
Immunohistochemistry (IHC) staining was performed on 4-um-thick slides of FFPE using a Ventana anti-ALK (D5F3) rabbit monoclonal primary antibody combined with the OptiView DAB IHC Detection Kit and the OptiView Amplification Kit (Ventana Medical Systems, Inc. Tucson, AZ). Each patient had a matched negative control slide to assess non-specific background staining and the degree of background staining known to occur as a result of 
Evaluation of the Response to Crizotinib in a Patient With ALK Rearrangement
One patient with ALK-rearranged PSC was treated with crizotinib. Chest and upper abdomen computed tomography (CT) scans were performed at the baseline and every two cycles of crizotinib treatment. Treatment responses were evaluated according to the response evaluation criteria for solid tumors (RECIST) version 1.1.
Statistical Analysis
All data were processed with SPSS version 22.0 (SPSS Inc., Chicago, IL). The Fisher's exact test was used to compare the clinical-pathologic characteristics of ALK arrangement-positive and-negative PSCs. A two-sided P value ≤.05 was considered statistically significant.
Results
Patient Characteristics
A total of 141 histologically confirmed PSCs from six medical centers were enrolled for ALK arrangement analysis. The clinical parameter and tumor features of all patients are shown in Table 1 . The median age of patients was 59 (range, 28-84) with 51.1% of patients being older than 60. The majority of patients with PSC were male (87.2%) and had smoking history (66.7%). The most common pathologic subtypes were pleomorphic carcinoma (66.7%), followed by spindle-cell carcinomas (14.6%) and carcinosarcoma (9.7%). EGFR mutations were identified 5 of 32 cases (15.6%), and KRAS mutations were found in 2 of 12 patients (16.7%). Table 2 . Two were carcinosarcomas with a stage Ib (pT2bN0M0) tumor and a stage IIIb (pT4N2M0) tumor, respectively, occurring in never-smoked men. The other three were pleomorphic carcinomas, and their clinical stages were stage IV (cT4N1M1a), stage Ia (pT1aN0M0), and stage Ib (pT2N0M0), respectively. Of all five tumors, four of them had adenocarcinoma epithelial components, and the other one had squamous cells carcinoma epithelial components. Strong positive ALK rearrangement was observed in both the carcinomatous and sarcomatoid components of all five tumors (Figures 1 and 2) . ALK rearrangement was found to be mutually exclusive with mutations in EGFR and KRAS. The characteristics of the ALK rearrangement-positive and the ALK rearrangement-negative PSCs were compared in Table 3 . The median age of ALK-positive patients was younger than that of ALK-negative patients (52 years vs. 57 years). PSCs in never-smokers were more likely to harbor ALK rearrangement than those in former or current smokers (P = .046). There was no significant difference in the incidence rates of ALK rearrangement among different histological subtypes of PSC.
Dramatic Response to Crizotinib in a Patient With Advanced PSC and ALK Rearrangement
A 40-year-old woman (case 3 in Table 2 ) without tobacco exposure visited our hospital because she had a persistent cough. A chest computed tomography screen found irregular lesions in the left hilar and the pleura. Subsequent fluorodeoxyglucose positron emission tomography (FDG-PET) showed abnormally high uptake in those lesions, and no brain metastasis was detected by brain magnetic resonance imaging (MRI). In transbronchial biopsy specimens, sarcomatoid spindle cells and polygonal epithelioid cells proliferated without distinct architectural features. IHC demonstrated positive for pancytokeratin and vimentin and negative for thyroid transcription factor-1 (TTF-1) and other mesenchymal markers such as S-100, desmin, bcl-2, and CD34. Thus, the disease was diagnosed as stage IV (T4N1M1a) pleomorphic carcinomas. Expanded molecular testing revealed ALK rearrangement in the tumor, and no EGFR/KRAS mutations, ROS1 rearrangement, and c-Met amplification were detected. Therefore, the patient started crizotinib 250 mg orally twice daily. She achieved an excellent radiographic partial response (−32%) after 3 months of treatment (Figure 3) . At the time of this report (11 months), the patient is continuing on crizotinib without evidence of disease progression and without any severe side effects.
Discussion
There are currently few therapeutic options for patients with PSC, and there are few new insights into the EGFR and KRAS mutations in PSC, and there has been fairly little research conducted on the aspect of ALK rearrangement [8, 9, 15, 16] . Therefore, we carried out this large sample size, multi-center study, and we identified ALK rearrangement in 3.5% of PSC. We also found that PSCs in younger never-smokers were likely to harbor ALK rearrangement. An excellent partial response to the ALK inhibitor crizotinib in a woman with advanced PSC and ALK rearrangement provides clinical validation and translatability of ALK-targeted therapy in PSC.
The incidence rates of ALK rearrangement in PSC remain unknown. Previously, almost all of the studies using a small sample size have reported that no ALK rearrangement occurred in PSC [10, 11] . Recently, a few cases of ALK rearrangement-positive PSC have been reported in Japan [12] [13] [14] . In our large sample study, the incidence rate of ALK rearrangement in PSC was 3.5%, which is similar to the frequency in typical NSCLC. The previous controversy of the incidence rates may partly be a result of the bias caused by the small sample sizes. Notably, until now, almost all reported ALK rearrangement-positive PSCs were from studies based on the East Asian population. Therefore, we also speculate that PSCs in the East Asian population are more likely to harbor ALK rearrangement. The clinical profile of patients with ALK-rearranged PSC is similar to that of typical ALK-rearranged NSCLC. Both previous reports and our present study revealed that ALK rearrangement is more likely to be detected in PSCs with adenocarcinoma components of younger never-smoked patients [12] [13] [14] . Another intriguing observation we found involves two patients with carcinosarcoma harboring ALK rearrangement. To the best of our knowledge, no ALK-rearranged pulmonary carcinosarcoma has been reported previously. Pulmonary carcinosarcoma has a predilection to occur in older males and is also well associated with heavy smoking [17, 18] . However, both of the two patients with ALK-rearranged PSC in our study were younger never-smoked men. Identifying these clinical and histological characteristics will help us to find out patients most likely to harbor ALK-rearrangement and to benefit from ALK-targeted therapy.
We described a patient with ALK-rearranged PSC who showed a partial response to crizotinib treatment by 3 months, and this benefit was still seen on the follow-up CT images at 8 months. Murakami et al. treated a 50-year-old never-smoked man who had pleomorphic carcinomas harboring ALK rearrangement with crizotinib, and achieved a partial response by 1 month [13] . However, the disease progressed after 3 months due to new liver and brain metastases. The exact reason for this discrepancy is not known. Therefore, further clinical trials are needed to verify the efficiency of ALK-targeted therapy in patients with ALK-rearranged PSC.
In summary, the incidence rates of ALK rearrangement in PSC in the Chinese population are similar to those of other subtypes of NSCLC. PSCs in younger never-smokers are more likely to harbor ALK rearrangement. ALK inhibitors may serve as an effective treatment for ALK-rearranged PSC.
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